LAS VEGAS, NV / ACCESSWIRE / April 20, 2023 / Cannabis Sativa, Inc. (OTCQB:CBDS) announces that PrestoDoctor will give on-site evaluations at the 9th annual Pennsylvania Cannabis Festival, Pocono 420, at the Pocono Raceway in Long Pond, Pennsylvania on April 22-23.
"Attendees seeking a medical cannabis recommendation will be able to complete their medical evaluation quickly and easily at the festival," stated COO Rob Tankson. "During events, we integrate our proprietary technology to expedite the signup and application process while maintaining our commitment to privacy. PrestoDoctor has completed well over 100 in-person events to date."
Guests have access to hundreds of vendors, dozens of food trucks, discussion panels, live music, and infield camping for cars and RVs.
PrestoDoctor is a Green Sponsor for Pocono 420.
About PrestoDoctor
PrestoDoctor is rated the #1 online medical marijuana doctor by thousands of medical cannabis patients who have received fully qualified medical marijuana recommendations. PrestoDoctor is the only service to offer patients a custom treatment plan after they have a confidential evaluation with a licensed, highly knowledgeable physician who is an expert in treatment methods, dosing levels, and cannabis products. Founded in 2015, PrestoDoctor services are available in legal medical marijuana states: California, Missouri, New York, Nevada, Oklahoma, Pennsylvania, Illinois, Iowa, Texas and Louisiana. A HIPAA and HITECH compliant telemedicine company, PrestoDoctor is a member of the American Telemedicine Association (ATA), maintaining the highest customer satisfaction rating for any telemedicine service online with over 20,000 5-star reviews.
About Cannabis Sativa, Inc.
Cannabis Sativa, Inc. ("CBDS") is engaged in telehealth, and the licensing of cannabis-related intellectual property, marketing and branding for cannabis-based products and services, operation of cannabis-related technology services, and ancillary business activities. CBDS holds a U.S. patent on the Ecuadorian Sativa strain of Cannabis, a U.S. Patent for a marijuana lozenge; a Cannabis-based pharmaceutical composition for the treatment of hypertensive disorders by submucosal delivery and trade secret formulas and processes, and operates subsidiary PrestoDoctor®.
Forward-Looking Statements
This press release contains "forward-looking statements." Although the forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subject to known and unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by us in our reports filed with the Securities and Exchange Commission, including the risk factors that attempt to advise interested parties of the risks that may affect our business, financial condition, and results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Underlying assumptions include without limitation, the ongoing enactment of legislation favorable to the production of and the commercialization of cannabis products and the Company's success in capitalizing on that legislation. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Contact Information:
(702) 762-3123
SOURCE: Cannabis Sativa, Inc.